CEL-SCI Corp.
(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 7.68%161.380.0%$1898.51m
OCGNOcugen, Inc. 6.32%8.750.0%$1079.84m
BNTXBioNTech SE 6.63%192.770.0%$872.52m
AMGNAmgen, Inc. 0.43%251.381.3%$740.91m
NVAXNovavax, Inc. 8.84%131.6979.8%$572.50m
SNSSSunesis Pharmaceuticals, Inc. 0.26%7.680.7%$536.86m
GILDGilead Sciences, Inc. -0.55%68.531.0%$504.56m
REGNRegeneron Pharmaceuticals, Inc. -0.11%516.622.7%$432.65m
ALXNAlexion Pharmaceuticals, Inc. 0.09%173.492.0%$412.31m
VRTXVertex Pharmaceuticals, Inc. 1.28%217.091.9%$311.54m
ILMNIllumina, Inc. 2.03%381.033.5%$302.74m
BIIBBiogen, Inc. -0.53%280.211.7%$269.43m
VXRTVaxart, Inc. 4.92%6.610.0%$240.79m
CRSPCRISPR Therapeutics AG 5.58%106.640.6%$171.41m
BNGOBionano Genomics, Inc. 22.45%5.400.0%$162.77m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.